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Abstract
Post-transplant lymphoproliferations (PTLDs) are the cancer with the highest incidence 
after cardiac transplantation. The World Health Organization (WHO) has defined sev-
eral specific entities: clonal or non-clonal, early, polymorphic or monomorphic. Early 
PTLDs being generally positive for Epstein-Barr virus (EBV), preventive and preemp-
tive treatments have been proposed; the former did not lead to effective attitudes, unlike 
preemptive treatment, based on EBV viral load monitoring the first year, which pro-
poses a decrease of the immunosuppression with or without rituximab according to the 
viral load and the answer to the immunosuppression decrease. The curative treatment 
of CD20 positive PTLDs, the most frequent form, begins to be codified; it starts with a 
decrease in immunosuppression and then uses rituximab monotherapy and, depending 
on the response, either only rituximab or four courses of R-CHOP. By following this man-
agement, the incidence of early PTLDs decreases and the treatment of PTLDs provides 
survivals close to that of other transplant patients.
Keywords: post-transplant lymphoproliferation, epstein barr virus, lymphoma, 
rituximab
1. Introduction
Non-Hodgkin’s lymphoma (NHL) is the cancer with the highest incidence after cardiac trans-
plantation. However, NHL is only part of the PTLD, the WHO recognizing several entities, 
whose lymphomatous and/or clonal appearance is not systematic. Since PTLDs are often 
linked to Epstein-Barr virus (EBV), preventive and above all preemptive treatments have been 
proposed to reduce the incidence of these proliferations. The prognosis of PTLD is generally 
presented as severe; however, the latest therapeutic proposals, adapted to the response to ritux-
imab, provide survivals close to those of the rest of the population of transplanted patients.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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2. Epidemiology
It is usual in the literature to estimate between 3 and 5% the risk of a cardiac-transplanted patient 
developing a PTLD [1]; however, these figures are old and vary depending on immunosup-
pression and duration of patients’ lives, fortunately improved in the last 10 years. The largest 
study on the epidemiology of PTLD [2] involved 175,732 organ transplants between 1987 and 
2008, including 10% of heart transplants. Pulmonary cancers represent the most frequent cancers 
(386/100,000/years) just in front of the NHL (283/100,000/years) but the standardized incidence 
ratio (SIR) of the NHL is very clearly superior to that of all the other cancers. Table 1 presents 
the incidence and the SIR of the main cancers according to the transplanted organ. The risk of 
PTLD persists as long as immunosuppression is used, that is, until death for cardiac transplant 
patients; it is maximum the first year after transplantation, with an SIR greater than 10, but 
remains stable thereafter, with a SIR between 3 and 10 for a follow-up of up to 15 years.
EBV, initially described as always associated with PTLDs, is actually only half of the time. 
Almost always found in children, most often on the occasion of a primary infection, and in 
early forms (before the first year after transplantation), it has become rare in the late forms, 
the most common situation of our days [3]. In cerebral PTLDs, representing 10% of PTLDs, 
EBV is almost always found [4].
3. Diagnosis
3.1. Definition: anatomopathology
PTLDs, as their name suggests, are lymphoid proliferations occurring after solid or hemato-
poietic organ transplantation and are authentic entities recognized in the WHO classification 
[5], presented in Table 2. We will retain some peculiarities to this classification:
• Early lesions are almost always EBV positive.
• Polymorphic lesions (infiltration by cells of different types) are polyclonal in almost half 
of the cases.
• Monomorphic lesions are clonal.
Transplanted organ Cancer: incidence (100,000/years)/SIR
NHL Lung cancer Liver cancer Kidney cancer
Heart 283/7.79 386/2.67 13.8/1.02 90.1/2.90
Kidney 141/6.05 115/1.46 10.7/1.08 126/6.66
Liver 217/7.77 178/1.95 495/44 39.9/1.80
Lung 532/18.73 626/6.13 17/2.04 34/1.49
Table 1. Incidence and SIR of the main cancers developed after transplantation depending on the transplanted organ.
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• The cerebral PTLDs are almost always monomorphic B lesions.
• B-type diffuse B-cell monomorphic lesions are by far the most common PTLD.
• Follicular lymphomas, marginal zone lymphomas, and mantle cell lymphomas are not 
considered PTLDs even when they occur after transplantation.
3.2. Diagnosis and extension assessment
The presentation of PTLDs is not unambiguous and the signs are not specific. In early forms, 
an alteration of the general status with fever is often present. In the other forms, the clinical 
signs depend on the tumoral localizations; for this reason, the digestive localizations are fre-
quent and can be a source of digestive disorders, pain, even perforation, or necrosis (Figure 1).
Early lesions Plasmacytic hyperplasia PTLD
Infectious mononucleosis PTLD
Florid follicular hyperplasia PTLD
Polymorphic PTLD
Monomorphic B PTLD Diffuse large B cell lymphoma
Burkitt lymphoma
Plasmacytoma-like
Monomorphic T PTLD T-cell lymphoma, non-otherwise specified
Hepatosplenic T-cell lymphoma
T/NK lymphoma
Classical Hodgkin lymphoma PTLD
Table 2. WHO classification for PTLD.




Paraclinically, the EBV viral load (EVL) is essential, and a high rate is in favor of an EBV-positive 
PTLD; it is also a good marker of response during treatment. Imaging, CT scanning, or especially 
PET-CT scan are diagnostic [6] and allow an adequate extension assessment. The appearance of 
tumors and nodes is similar to that of lymphomas of immunocompetent patients. In the particu-
lar case of cerebral PTLD, the lesions are necrotic, in the form of a cockade, identical to toxoplas-
mic lesions, as in patients with HIV (Figure 2). MRI spectrometry can point to PTLD rather than 
infection. In the absence of contraindication, a lumbar puncture is necessary; it must include a 
cytology with anti-CD20 labeling on a slide, a phenotyping, a search for B clonality, and an EBV 
viral load. If lumbar puncture is found in lymphoma cells, cerebral biopsy is not necessary.
4. Treatment
4.1. Preventive treatment
Preventive treatment is defined as a systematic treatment that can avoid or reduce the inci-
dence of PTLDs; it only concerns EBV-positive PTLDs. In this area, no study specifically tar-
gets heart-transplant patients. The interest of antivirals, especially ganciclovir, does not seem 
to be confirmed. On the other hand, polyvalent CMV immunoglobulins (in fact rich in anti-
EBV immunoglobulins) have shown, in a retrospective study, an interest in kidney-transplant 
patients, suppressing the risk of PTLD occurring during the year of prevention in more than 
2000 patients [7], whereas no preventive effect was detected in patients receiving ganciclovir. 
However, a prospective study, admittedly of a smaller size, did not show any difference between 
a preventive treatment with ganciclovir + placebo versus ganciclovir + immunoglobulins against 
CMV [8]. Currently, no preventive treatment is recommended in cardiac-transplant patients.
4.2. Preemptive treatment
Preemptive treatment only concerns EBV-positive PTLDs; it consists of treating patients 
according to their EBV viral load. It is based on the fact that the majority of EBV-positive 
Figure 2. Cerebral PTLD, MRI in T1 with gadolinium.
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PTLDs are preceded by an increase in EBV load or a simple positivity in the case of primary 
infections [8]. The most classic attitude is to reduce immunosuppression, where possible 
[9–11]. As the EBV reservoir is the B lymphocyte, rituximab has also been used successfully 
in this setting, especially after allografts of hematopoietic stem cells [12]. Much less avail-
able and usable only in the context of protocols, anti EBV T lymphocytes, either autologous 
(taken from the patient and stimulated ex vivo) [13, 14], or allogeneic (from healthy donor 
lymphocyte banks) [15], have been used effectively in case of EBV reactivation. Specifically 
developed in cardiac-transplant patients, a treatment algorithm has been validated on nearly 
300 patients whose immunosuppression was identical [16]; it is based initially on the sero-
logical status before transplant and then on the EVL carried out at each follow-up visit, for 
at least 1 year. The algorithm is described in Figure 3. In summary, immunosuppression 
is reduced as soon as the EVL is positive if the recipient was seronegative, since it is then 
a primary EBV infection, that is, when the EVL is greater than 105 copies/ml in other case. 





An injection of 375 mg/m2 of rituximab is performed, in addition to the decrease in immu-
nosuppression, if the EVL is greater than 106 copies/ml, or if the initial decrease in immu-
nosuppression fails. No cases of EBV-positive PTLD were diagnosed in this series, which is 
statistically significant in historical comparison with more than 800 patients transplanted in 
the same unit before using this algorithm.
4.3. PTLD treatment
4.3.1. Decrease of the immunosuppression
The decrease in immunosuppression remains the benchmark for the initial management of 
PTLDs. It allows complete response in less than 10% of cases, mainly in early forms [17, 18]. 
As the median time of response is 3.6 months [19], it is conventional to wait 4 weeks before 
evaluating the response to the decrease of immunosuppression, except in case of progression. 
Even in the event of failure, it is necessary to keep the immunosuppression as low as possible 
because it seems to potentiate immunochemotherapy [20].
4.3.2. Immunochemotherapy
In the case of failure of the reduction of immunosuppression, in CD20-positive PTLDs, 
which represents the vast majority of cases, sequential immunochemotherapy is the refer-
ence treatment, validated by two European prospective studies [3, 21]. The processing algo-
rithm is shown in Figure 4. The first phase is to use only rituximab monotherapy and wait 
3 weeks before evaluating the response, in case of complete remission, which is found in 
one-third of cases; rituximab is continued alone, this to avoid chemotherapy, in other cases, 
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is used, a 
reference chemotherapy of NHL, but only for four cures against six to eight in the immuno-
competent patients, and a case is presented in Figure 5. This therapeutic attitude gives 88% 
of response, 70% of complete response, and a median survival of 6.6 years, which currently 
constitutes the best results of the literature for a prospective study. In pediatric patients, 
lightened chemotherapy regimens have been proposed, without doxorubicin or vincristine, 
making it possible to obtain an overall survival of 83% at 2 years and an event-free survival 
of 71% [22].
4.4. Specific PTLDs
4.4.1. PTLD of the central nervous system
PTLDs in the central nervous system account for 10% of PTLDs, and even if they occur 
mostly after kidney transplants, they are not uncommon after cardiac transplantation. 
Their management is not consensual but should include if possible a reduction of immuno-
suppression and methotrexate adapted to the renal function, and the addition of aracytine 
and rituximab is recommended. In case of failure or contraindication, radiotherapy is an 
option. In a recent retrospective study, the response rate was 60% but the 3-year survival 
was only 43% [4].
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4.4.2. Classical Hodgkin PTLD
Hodgkin PTLD should be treated as Hodgkin’s immunocompetent patients, without ritux-
imab (Hodgkin’s are CD20 negative); their prognosis is excellent.




4.4.3. Plasmacytic hyperplasia PTLD
This rare form of early lesions can be treated with radiotherapy or lymphoma chemotherapy.
4.4.4. T-cell lymphoma PTLD
This type of PTLD has a very poor prognosis, rituximab is useless and the classic chemother-
apy-type CHOP has little effectiveness. In case of localized form, radiotherapy may be useful.
4.4.5. Relapses
Relapses after complete remission are rare; if they occur late after the first PTLD, a com-
parison of the clones is necessary because a second PTLD, independent of the first one, is 
possible; if it is the case, the algorithm of first line, describes previously, can be reused, 
and the maximum dose of anthracycline will not be reached. In other cases, NHL treat-
ments of immunocompetent patients in relapse may be used, even hematopoietic stem cell 
autograft.
4.5. Cell therapy
Cell therapy is not yet available outside study protocols. Its principle is to use T cells spe-
cifically directed against EBV antigens, so it is only applicable to half of PTLDs. It is mostly 
the allogeneic lymphocyte banks, from healthy donors, that are promising. The lympho-
cytes are selected according to the HLA typing of the tumor. In the Scottish experience, 12 
Figure 5. Response of a monomorphic diffuse large B cell PTLD after four rituximab and after four R-CHOP.
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complete remissions were obtained from 33 treated patients, but many of these patients 
had not received rituximab in the first line [23]. The ATARA Biotherapeutics laboratory 
begins in 2018, a phase 3 study using allogeneic anti-EBV lymphocytes against placebo in 
relapsed or refractory PTLDs, which could allow in the medium term to offer this therapy 
to all centers treating PTLDs.
4.6. CAR-T cells and anti-PD1/anti-PDL1
CAR-T cells, which are being developed in lymphoid hemopathies of immunocompetent 
patients, have not yet been used in an immunocompromised context that could potentially 
reduce their effectiveness.
Anti-PD1/PDL1 antibodies by improving immunity expose patients to rejection of the trans-
planted organ, sometimes abruptly; their indication in PTLDs, mainly of Hodgkin type, is 
strongly discouraged and should only be proposed by the last resort [24].
5. Conclusion
PTLDs are a clearly defined entity, representing the most increased cancer among cardiac-
transplant recipients compared to the general population. Its management, from preemptive 
treatment to curative treatment, has been considerably improved in order to obtain a survival 
rate similar to that of other transplant recipients. The treatment deviates significantly from 
that of immunocompetent lymphomas and requires management by teams accustomed to 
this type of pathology, both for the follow-up of the transplant and for the hematological 
treatment. The development of cell therapies is very likely the next step in progress.
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